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Abstract
Hypermutable or mutator microorganisms are those that have an increased spontaneous mutation rate as a result of defects in DNA
repair or error avoidance systems. Over the last two decades, several studies have provided strong evidence for a relevant role of
mutators in the evolution of natural bacterial populations, particularly in the ﬁeld of infectious diseases. Among them, chronic respira-
tory infection with Pseudomonas aeruginosa in cystic ﬁbrosis (CF) patients was the ﬁrst natural environment to reveal the high preva-
lence and important role of mutators. A remarkable positive selection of mutators during the course of the chronic infection has been
reported, mainly as a result of the emergence of DNA mismatch repair system (mutS, mutL or mutU)-deﬁcient mutants, although strains
defective in the GO system (mutM, mutY and mutT) have also been observed. High frequencies of mutators have also been noted among
other pathogens in the CF setting, particularly Staphylococcus aureus and Haemophilus inﬂuenzae. Enhanced antimicrobial resistance devel-
opment is the most thoroughly studied consequence of mutators in CF and other chronic infections, although recent studies show that
mutators may additionally have important effects on the evolution of virulence, genetic adaptation to the airways of CF patients, persis-
tence of colonization, transmissibility, and perhaps lung function decline. Further prospective clinical studies are nevertheless still needed
for an in-depth evaluation of the impact of mutators on disease progression and outcome.
Keywords: Adaptation, antibiotic resistance, chronic infection, cystic ﬁbrosis, hypermutation, mutator, Pseudomonas aeruginosa, review
Clin Microbiol Infect 2010; 16: 798–808
Corresponding author and reprint requests: A. Oliver, Servicio
de Microbiologı´a, Hospital Son Dureta, C. Andrea Doria No. 55,
07014 Palma de Mallorca, Spain
E-mail: antonio.oliver@ssib.es
Introduction
Hypermutable (or mutator) microorganisms are those that
have an increased spontaneous mutation rate as a result of
defects in DNA repair or error avoidance systems. Over the
last few decades, several theoretical experiments, performed
both in vitro and in vivo, have shown that mutator phenotypes
confer an evolutionary advantage during bacterial adaptation
to new environments or stressful conditions [1–5]. These
investigations demonstrated that mutator cells, present in
regular bacterial populations at a rate of the order of 10)5
as a consequence of spontaneous mutations in DNA repair
genes, can be dramatically ampliﬁed by co-selection (hitchhik-
ing) with adaptive mutations, playing a major role in bacterial
evolution. Adaptation to the host immune system [6], anti-
biotic treatment [7] or viral parasites [8] has indeed been
shown to be accelerated in mutator backgrounds in various
experimental models. Further studies have provided strong
evidence for a relevant role of mutators in the evolution of
natural bacterial populations, particularly in the ﬁeld of infec-
tious diseases [9–12]. Among them, chronic respiratory
infection (CRI) with Pseudomonas aeruginosa in cystic ﬁbrosis
(CF) patients was the ﬁrst natural model to reveal the high
prevalence and important role of mutators [10]. Antimicro-
bial resistance development and bacterial adaptation during
chronic infections are among the most relevant evolutionary
traits linked so far to hypermutation in nature [10,13]. Cur-
rent knowledge concerning the prevalence, mechanisms and
consequences of bacterial mutators in CF CRI are reviewed.
Genetic Basis of Hypermutation
The mutator phenotype is consequence of a defect in one of
the several DNA repair or error avoidance systems and, for
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this reason, the genes involved are generally referred to as
(anti)mutator genes [14,15] (Table 1). Among them, the mis-
match repair (MMR) system is especially important not only
because its alterations are the most frequent cause of hyper-
mutation in natural bacterial populations, but also because
they are a frequent driver of human cancer [16].
The MMR system detects and repairs replication errors
including any kind of mispairs and short insertions or deletions.
The inactivation of any of the key genes involved (mutS, mutL
and mutH, as well as uvrD or mutU) increases the rate of muta-
tion from 100- to 1000-fold and the spectra of mutations pro-
duced include G:C ﬁ A:T and A:T ﬁ G:C transversions and
deletions or insertions of 1–4 bp [17]. In Escherichia coli, the
recognition of the mismatch by the MMR system relies on the
methylation of the parental strand but not of the daughter
strand at GATC sequences by Dam methyltransferase. For this
reason, this system is also called the Dam-directed mismatch
repair system. MutS recognizes and binds to the mismatch,
MutL interacts with MutS and together activates the endonu-
clease MutH that cleaves the non-methylated strand at the
GATC sequence. Unwinding by helicase II (UvrD) and excision
and repair can then proceed in either the 5¢ or 3¢ direction.
Not all microorganisms, including P. aeruginosa, have dam and
mutH homologues, and therefore the recognition of the daugh-
ter strand is not based on DNA methylation but on alternative
recognition pathways.
In addition to the activity of the MMR system preventing the
accumulation of mutations as a result of replication errors, this
system is also the most potent inhibitor of recombination
between weakly and moderately diverged (homeologous)
sequences, including genomes of related bacteria such as E. coli
and Salmonella [18]. Therefore, the inactivation of the MMR sys-
tem, in addition to increasing the mutation rates, increases the
rates of homeologous recombination, facilitating the acquisition
of exogenous DNA through horizontal gene transfer [19].
Mutations in dnaQ (mutD) coding for the epsilon subunit
of the DNA polymerase III that has proofreading activity lead
to a very strong mutator phenotype, increasing the mutation
rate by up to 10 000-fold. The spectra of mutations pro-
duced include all types of base substitutions and frameshifts.
Mutations in this gene also reduce the growth rate and have
not been found in natural bacterial populations. Other muta-
tor genes include mutM, mutY and mutT, which are involved
in the system that prevents mutations caused by the oxida-
tive lesion 8-oxodG (GO system). Mutations in mutM and
mutY lead to a weak and moderate mutator phenotype,
respectively, speciﬁcally increasing the rate of G:C ﬁ T:A
transversions. On the other hand, mutations in mutT lead to
a strong mutator phenotype increasing the rate of
A:T ﬁ C:G transversions. Finally, other mutator genes com-
prise those involved in the prevention of oxidative damage
produced by reactive oxygen species, such as oxyR and sodA,
mutator tRNAs (mutA and mutC) [14] or radA and pfpI, as
recently characterized in P. aeruginosa [20,21].
In addition to the stable mutator phenotypes produced by
the alteration of the mutator genes, under particular circum-
stances (e.g. when DNA is damaged), a transient mutator phe-
notype is produced by the induction of the error-prone DNA
polymerases (DNA polymerases IV and V) as part of the SOS
response [22,23]. Some antibiotics may actually induce a tran-
sient mutator phenotype through this mechanism, promoting
the development of antimicrobial resistance [24–26].
Laboratory and Theoretical Evidence for a
Role of Hypermutation in Adaptive Evolution
Laboratory and theoretical approaches have shown that,
under particular circumstances, such as exposure to new envi-
ronments or stressful conditions, mutator cells maybe
TABLE 1. Principal mutator genes, most functionally characterized in Escherichia coli
Gene Product activity Mutations produced Mutator effect
mutD (dnaQ)  subunit of DNA pol III, proofreading activity All base substitutions, frameshifts Very strong
MMR system
mutS DNA mismatch recognition, binds mismatches GC ﬁ AT, AT ﬁ GC, frameshifts Strong
mutL Interacts with MutS and MutH
mutH Endonuclease, nicks hemi-methylated GATC sequences
uvrD DNA Helicase II, strand displacement
dam DNA adenine methyltransferase, strand recognition
GO system
mutT Nucleoside triphosphatase, prevents incorporation of 8-oxoG to DNA AT ﬁ CG Strong
mutM DNA glicosylase, removes 8-oxoG from 8-oxoG-C mispairs G:C ﬁ T:A Weak
mutY DNA glicosylase, removes A from 8-oxoG-A or A-G mispairs G:C ﬁ T:A Moderate
mutA GlyV, glycyl tRNA AT ﬁ TA, GC ﬁ TA, AT ﬁ CG Weak–moderate
mutC GlyW, glycyl tRNA AT ﬁ TA, GC ﬁ TA, AT ﬁ CG Weak–moderate
ung Uracil glicosylase, removes U from U-G mispair GC ﬁ AT Weak–moderate
sodA, sodB Superoxide dismutase, removes superoxide radicals AT ﬁ TA Weak
oxyR Regulates hydrogen peroxide inducible genes AT ﬁ TA Weak
polA DNA polymerase I Frameshifts, deletions Weak–moderate
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selected in a bacterial population by hitchhiking with adapting
mutations [1–3,27]. For example, Sniegowski et al. [2] found
that, in E. coli populations evolving for 10 000 generations in a
glucose-limited environment, there is a frequent ascent to
dominance of mutator variants. These ﬁndings were consistent
with simultaneously reported computer simulations of bacte-
rial evolution [3]. A good example of how mutator cells can
be ampliﬁed in a bacterial population by hitchhiking with
adapting mutations was provided by Mao et al. [4]. In that
study, it was found that when E. coli populations are subjected
to a one-step mutation selection process (i.e. culture in a med-
ium in which only particular mutant colonies can grow), hyper-
mutable variants were ampliﬁed in the population from
approximately 0.001% to 0.5% and, when they were subjected
to two consecutive steps of mutant selection, the ampliﬁcation
reached 25–100%. A similar ampliﬁcation of MMR-deﬁcient
mutator cells has been found after selection for recombinants
in interspecies mating between Salmonella and E. coli [19].
These results demonstrate that horizontal gene transfer may
also select for hypermutable variants during adaptive evolution
as a result of the increased rate of homeologous recombina-
tion of MMR-deﬁcient cells. Finally, using a murine model of
E. coli intestinal colonization, Giraud et al. [5] found that
hypermutation was initially beneﬁcial because it allowed a fas-
ter adaptation to the mouse gut environment, although this
advantage disappeared once adaptation was reached, and the
transmissibility of the hypermutable strains was then consider-
ably reduced. More recently, Pal et al. [8] showed that the co-
evolution with viral parasites could be an important driver of
the evolution of bacterial mutation rates in laboratory popula-
tions of Pseudomonas ﬂuorescens. After fewer than 200 bacte-
rial generations, 25% of the populations co-evolving with
phages had evolved ten- to 100-fold increases in mutation
rates owing to mutations in MMR genes; no populations evolv-
ing in the absence of phages showed any signiﬁcant change in
mutation rates. Furthermore, mutator populations had a
higher probability of driving their phage populations to extinc-
tion, strongly suggesting that mutators have an advantage
against phages in the co-evolutionary arms race.
Further laboratory experiments, using P. aeruginosa as
model microorganisms, have shown that hypermutation has
major effects on the evolution of bacterial cooperation and
virulence [28,29].
Prevalence of Mutators in Natural Bacterial
Populations
The prevalence of mutators in natural populations was ﬁrst
explored in E. coli and Salmonella, and was found to be higher
than expected (approximately 1%) [9,30]. These ﬁndings, in
concordance with the results obtained via in vitro experiments,
suggested that hypermutation could act as a mechanism for
acceleration of bacterial evolution in nature. The ﬁrst evidence
for a speciﬁc environment driving the selection of hypermut-
able strains in natural populations was obtained in a study
of P. aeruginosa CRI in CF patients in which the prevalence of
hypermutable strains was by far the highest ever found in nat-
ure [10]. Further work revealed that Staphylococcus aureus and
Haemophilus inﬂuenzae from CF patients are also frequently hy-
permutable [31–33]. The association between mutators and
chronic infections extends beyond CF because hypermutable
P. aeruginosa has also been found to be very prevalent in other
CRI, such as those occurring in patients with bronchiectasis or
chronic obstructive pulmonary disease (COPD) [34,35]. On
the other hand, the prevalence of mutator P. aeruginosa has
been shown to be low in acute infections [10,36]. Additional
links to chronicity might also be seen in the case of E. coli
because the inactivation of the MMR system was shown to
increase the chronic persistence of urinary tract infections
(UTI) in mouse models [37], and mutator strains appear to be
particularly frequent among clinical UTI isolates [38]. Mutator
strains have additionally been documented in natural popula-
tions of Helicobacter pylori [39], Neisseria meningitidis [40] Strep-
tococcus pneumoniae [41], Mycobacterium tuberculosis [42],
Klebsiella pneumoniae [43], Vibrio parahaemolyticus [44] and
Stenotrophomonas maltophilia [45], with variable prevalences.
Particularly noteworthy, a link between hypermutation and epi-
demicity was demonstrated for N. meningitidis [40,46]. The epi-
demicity of this microorganism is dependent upon its success
in adapting to different human hosts, which is achieved by sto-
chastically altering its surface composition by a mechanism of
phase variation mediated by mutations in homopolymeric DNA
direct repeats. Remarkably, approximately 50% of the highly
epidemic and virulent serogroup A N. meningitidis isolates were
found to be defective in the MMR system, expressing a rate of
phase variation >100-fold higher than wild-type isolates. A pos-
sible link between hypermutation and the success of the epi-
demic, highly disseminated W-Beijing clone of M. tuberculosis
has also been studied. Ebrahimi-Rad et al. [42] found that W-
Beijing genotype strains displayed unique missense alterations
in three putative mutator genes, including two homologues of
mutT, although other studies reported no differences in the
mutation rates of Beijing and non-Beijing strains [47].
Mutators in CF CRI
CF, caused by mutations in the gene that encodes the CF
transmembrane conductance regulator, is the most prevalent
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autosomal-recessive hereditary disease in Caucasian popula-
tions. Amongst other repercussions, this defect leads to an
alteration of respiratory secretions and determines a predis-
position for chronic bronchopulmonary colonization/infec-
tion, which is the main driver of the high morbidity and early
mortality of CF patients [48]. Colonization with S. aureus
and H. inﬂuenzae is frequent in children aged less than
10 years, whereas P. aeruginosa is by far the most relevant
pathogen in adults with CF and is responsible for the pro-
gressive bronchopulmonary deterioration [49].
In an initial study published in 2000, an extremely high prev-
alence (20% of isolates, 37% of patients) of P. aeruginosa muta-
tor strains was found in chronically colonized CF patients from
Spain [10]. These numbers notably contrasted with an absence
of mutator strains in acute P. aeruginosa nosocomial infections
from the same study, and with the existing data on E. coli and
Salmonella natural populations, in which 1% of mutators was
already considered to represent a high prevalence [9,30].
Further studies conﬁrmed and extended these initial
observations. In a cross-sectional study, Ciofu et al. [50]
detected mutator strains in 54% of Danish CF patients who
were chronically colonized with P. aeruginosa. The same
study included also a longitudinal (up to 25 years) evaluation
of the prevalence of P. aeruginosa mutator strains in CF
patients; remarkably, the proportion of hypermutable isolates
increased from 0% at onset/early colonization to 65% after
20 years of chronic colonization.
Other studies [13,51,52] had noted a certain prevalence
(approximately 5–10%) of hypermutable isolates already at
onset/early colonization. Indeed, the reported prevalence of
mutators during initial colonization could well reﬂect their
basal prevalence in the environment (i.e. the main source for
P. aeruginosa colonizing CF patients) because 6% of isolates
from environmental samples were found to be mutators in a
recent study [51]. Nevertheless, an overwhelming positive
selection of mutators during the course of CF chronic infec-
tion has always been documented [13,50,52]. Furthermore,
the positive selection of mutators appears to be a common
feature of chronic infections, and not exclusively of CF-asso-
ciated infections, because an extremely high prevalence (53%
of isolates, 57% of patients) of hypermutable strains has been
documented in patients with COPD or bronchiectasis [34].
Taken together, the available data [10,36] apparently indicate
a negative selection of mutators in acute nosocomial infec-
tions, with a prevalence of £1%.
Finally, Kenna et al. [51] investigated the prevalence of
mutators in representative isolates from different epidemic
CF strains. The proportion found (2/15; 13%) was not signiﬁ-
cantly higher than that documented for strains from onset/
early colonization in the same study. Indeed, the transmission
of mutator strains between CF patients has never been dem-
onstrated so far.
Regarding the genetic basis of hypermutation in
P. aeruginosa strains from CF patients, by far the most widely
investigated mechanism is that of the MMR system. Up to
60–90% of the mutator isolates from CF patients have a
defective MMR system, mainly caused by mutation of mutS
or mutL, and less frequently of uvrD (mutU) [13,52–54].
Considerably less information is available on the potential
involvement of other DNA repair systems in hypermutability.
P. aeruginosa was shown to have a conserved GO system
(mutM, mutY and mutT) [55], and a few mutator isolates from
CF patients failed to yield a positive result for mutY ampliﬁ-
cation in an initial study [10]. More recently, Mandsberg et al.
[56] and Ciofu et al. [54] have detected some mutT and a
mutY isolates among mutator strains from CF patients.
A higher prevalence of hypermutable strains in the CF set-
ting has also been noted for S. aureus and H. inﬂuenzae, dem-
onstrating that this phenomenon is not restricted to
P. aeruginosa only. Prunier et al. [31] found that approxi-
mately 14% of the S. aureus isolates from CF patients were
hypermutable in contrast to the approximately 1% from non-
CF patients. The same results (14% vs. 1%) were obtained
by Roma´n et al. [32] for H. inﬂuenzae. More recently, Besier
et al. [57] noted that S. aureus mutator phenotypes were
particularly frequent among thymidine-dependent small-col-
ony variants which are known to play an important role in
the pathogenesis and persistence of CF CRI. Regarding the
genetic basis of hypermutation in these microorganisms, the
most frequent cause also appears to be a defective MMR sys-
tem due to mutS or mutL mutations [31,33,57]. Finally, a
recent study has also documented the presence of mutS-deﬁ-
cient mutator strains of S. maltophilia in chronically colonized
CF patients [45].
As discussed below, enhanced antimicrobial resistance
development has been the most thoroughly studied conse-
quence of mutators in CF and other chronic infections,
although recent work shows that mutators may additionally
have important effects on the evolution of virulence, genetic
adaptation to the airways of CF patients, persistence of colo-
nization, transmissibility, and perhaps lung function decline
[10,13,50,52,58–63]. Table 2 summarizes the features associ-
ated with mutator strains from chronically infected CF
patients.
Mutators and Antibiotic Resistance
Over last decade, hypermutation has been increasingly rec-
ognized as a relevant problem for antimicrobial therapy
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[64,65]. The ﬁrst evidence for a role of mutators in antimi-
crobial resistance development was obtained from the model
of P. aeruginosa CRI in CF patients [10]. One of the most
striking characteristics of P. aeruginosa is its extraordinary
ability to acquire antibiotic resistance through the selection
of mutations in chromosomal genes [66]. This is an especially
critical factor in the management of chronic infections such
as those occurring in CF patients. After years of intensive
antibiotic chemotherapy in an effort to control the negative
outcome of chronic colonization, sequential development of
resistance to most antibiotics occurs frequently. Not surpris-
ingly, resistance rates among P. aeruginosa isolates from CF
patients are substantially higher than those found in isolates
from other settings, including those from patients in intensive
care units [67]. Subsequent to their ﬁrst description [10],
mutators were shown to play a major role in the high resis-
tance rates of CF isolates, thus representing an important
negative factor for the treatment of the CF CRI. Further-
more, when the rates of antimicrobial resistance were ana-
lyzed, mutators were found to be much more frequently
resistant than non-mutators to each of the eight antipseudo-
monal agents tested. Similar results were obtained later by
Ciofu et al. [50] in a large collection of CF P. aeruginosa iso-
lates from Denmark, and, more recently, by Ferroni et al.
[63] in CF isolates from France. The latter study additionally
analyzed the effect of hypermutation on the time required
for antibiotic resistance to appear, and demonstrated that
mutator strains acquired additional resistance mechanisms
much more quickly than non-mutator strains. In a highly
illustrative work, Henrichfreise et al. [60] investigated a
collection of 22 multidrug resistant (MDR) strains (resistant
to b-lactams, ﬂuoroquinolones and aminoglycosides) from a
multicentre study in Germany, 12 obtained from CF patients
and ten from non-CF patients. Remarkably, almost all (11/12)
of the CF strains were mutators, in which MDR had emerged
by combination of multiple mutation-mediated resistance
mechanisms. By contrast, MDR strains from non-CF patients
were mostly non-mutators in which horizontally acquired
resistance played a mayor role. Nevertheless, a strong link
between P. aeruginosa hypermutation and antibiotic resistance
has also been documented for non-CF CRI, such as those
occurring in patients with bronchiectasis or COPD [34].
A strong correlation between hypermutation and anti-
biotic resistance has also been observed for S. aureus and
TABLE 2. Features associated to mutator strains from chronically infected cystic ﬁbrosis (CF) patients
Publication
year Species Feature Description Reference
2000 Pseudomonas aeruginosa Antibiotic resistance Mutator strains showed higher resistance percentages to
ticarcillin, ceftazidime, imipenem, gentamicin, tobramycin,
norﬂoxacin, and fosfomycin
Oliver et al. [10]
2003 Staphylococcus aureus Antibiotic resistance Mutator strains were more frequently resistant to macrolides,
due to ribosomal mutations
Prunier et al. [31]
2004 Haemophilus inﬂuenzae Antibiotic resistance Mutator strains were linked to mutation-mediated resistance,
particularly ciproﬂoxacin resistance and the b-lactamase
negative ampicillin resistance (bLNAR) phenotypes
Roma´n et al. [32]
2005 Streptococcus pneumoniae Antibiotic resistance Signiﬁcant association of mutators with antibiotic resistance
was not observed
del Campo et al. [58]
2005 Pseudomonas aeruginosa Antibiotic resistance
DNA oxidation
Mutator strains showed higher MIC50 and MIC90 of ceftazi
dime, piperacillin-tazobactam, aztreonam, meropenem, tobra
mycin, and ciproﬂoxacin
Higher levels of 8-oxo-2¢-deoxyguanosine
Ciofu et al. [50]
2007 Pseudomonas aeruginosa Antibiotic resistance
Virulence
Fitness
Mutator strains showed higher antibiotic resistance rates
Mutator strains showed reduced cytotoxicity
Mutator strains showed reduced survival in tap water
Hogardt et al. [59]
2007 Pseudomonas aeruginosa Fitness Mutator strains showed reduced ﬁtness in vitro and in a
murine model of chronic respiratory infection
Montanari et al. [52]
2007 Pseudomonas aeruginosa Multidrug-resistance (MDR) Almost all MDR strains (resistant to b-lactams, ﬂuoroquinoles,
and aminoglycosides) from CF patients were mutators
Henrichfreise et al. [60]
2007 Pseudomonas aeruginosa Colistin susceptibility Mutator strains showed lower colistin MICs than non-mutator
strains
Macia et al. [61]
2008 Pseudomonas aeruginosa Accumulation of
adaptive mutations
Mutator strains acquired a higher number of mutations in 34
genes potentially involved in adaptation to the airways of CF
patients
Mena et al. [13]
2008 Pseudomonas aeruginosa Lung function
Mucoid phenotype
Patients colonized by mutator strains had poorer lung function
(% FEV1)
Mutator strains showed more frequently the mucoid
phenotype
Waine et al. [62]
2009 Pseudomonas aeruginosa Antibiotic resistance
Lung function
Mutator strains showed higher resistance percentages to
ticarcillin, ticarcillin+clavulanate, piperacillin, piperacillin-
tazobactam, cefsulodin, aztreonam, ceftazidime, imipenem,
tobramycin, amikacin, and ciproﬂoxacin
Mutator strains acquired additional resistance mechanisms
faster than non-mutator strains
Patients colonized by
mutator strains had poorer lung function (% FEV1)
Ferroni et al. [63]
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H. inﬂuenzae in the CF setting. Prunier et al. [31] noted that
a high proportion (53%) of the S. aureus isolates from CF
patients was resistant to erythromycin. Interestingly, more
than half of the resistant isolates did not contain any
acquired macrolide resistance gene but rather contained
mutations in rrl (23S rRNA), rplD (L4 protein) or rplV (L22
protein), which is very infrequent in macrolide-resistant
S. aureus isolates from other sources. This high prevalence of
mutational macrolide resistance was found to be associated
with a high prevalence of hypermutable strains in CF
patients. Similarly, Roma´n et al. [32] found a strong correla-
tion between the high prevalence of hypermutable H. inﬂuen-
zae strains in CF patients and high rates of mutational
antibiotic resistance. For example, CF isolates comprised sig-
niﬁcantly higher percentages of b-lactamase-negative ampicil-
lin-resistant isolates than non-CF isolates, whereas the rates
of b-lactamase-producing isolates was similar in both groups.
Of particular concern was the observation that up to 20% of
the H. inﬂuenzae strains from CF patients were resistant to
ciproﬂoxacin. It is worth noting that ciproﬂoxacin resistance
in H. inﬂuenzae is extremely infrequent in other settings and,
indeed, was not found in any of 188 non-CF strains from the
same study.
In addition to the clear statistical link between hypermuta-
tion and antibiotic resistance (i.e. mutators are more fre-
quently antibiotic resistant) found after the analysis of
collections of clinical isolates from CF patients, several in vitro
and in vivo experiments, as recently reviewed [68], further
highlight the dramatic consequences of hypermutation when
occurring in microorganisms such as P. aeruginosa that are
genetically equipped to acquire efﬁcient resistance to most
antibiotics by mutations in chromosomal genes [7,56,69–75].
Beyond Antibiotic Resistance: Role of
P. aeruginosa Hypermutation in Virulence,
Fitness, Transmissibility, Persistence and
Genetic and Metabolic Adaptation During
CF Lung Infection
The establishment of P. aeruginosa CRI is mediated by a com-
plex adaptive process that includes physiological changes pro-
duced by the activation of speciﬁc regulatory pathways,
including the induction of the bioﬁlm mode of growth or the
differential expression of virulence genes [76], as well as
genetic changes leading to the selection of an important
number of adaptive mutations required for long-term persis-
tence [77–79].
Although patients suffering from CRI are generally infected
with a single P. aeruginosa strain persisting in most cases all
through the patient’s life [80], one of the hallmarks of these
infections is the emergence, and ﬁxation over time, of multi-
ple phenotypic variants from the underlying clonal popula-
tions [10], a process known as adaptive radiation [81]. Many
of the selected phenotypes have been clearly linked to the
adaptation to the lung environment, thereby favouring
the lifelong persistence of CRI [79]. Long-term persistence in
the airways of CF patients appears to be driven by the selec-
tion of multiple, frequently loss-of-function, mutations leading
to an overall pattern of increased antimicrobial resistance,
adapted virulence (reduced acute injury but enhanced
chronic inﬂammation) and speciﬁc metabolic adaptation to
growth under microaerobic conditions created by suppura-
tive secretions in the lungs of CF patients [77,82–84].
The intense genetic adaptation process taking place during
the establishment of CRI has been recently quantiﬁed [77].
Whole-genome sequencing of early (6 month-old) and late
(96 month-old) P. aeruginosa isolates from a CF patient
revealed the acquisition of up to 68 mutations during the
establishment of the CRI. A clear signal of positive selection
was demonstrated because an extraordinarily high ratio of
nonsynonymous to synonymous mutations per site was doc-
umented. Indeed, many of the mutations detected lead to
the loss of function of the affected genes, which, of note,
were frequently involved in bacterial virulence. The work
was completed by the analysis of a collection of sequential
P. aeruginosa isolates from 29 additional CF patients; 24 of
the genes that had been mutated early in patient 1, and ten
additional genes that had been shown to be candidates for
mutation in many CF infections, were sequenced. Again, the
signal of positive selection of mutations in these genes was
overwhelming because only ﬁve synonymous mutations
accompanied 103 nonsynonymous mutations.
Using the same collection of strains, a recent study dem-
onstrated that this intense genetic adaptation process is cata-
lyzed by mutator strains [13]. Indeed, the presence of the
adaptive traits was found not to be homogeneous among the
CF isolates; by contrast, it was signiﬁcantly concentrated in
the MMR system-deﬁcient lineages. The documented differ-
ences in the rates of accumulation of mutations per year of
infection were certainly overwhelming: although sequential
non-mutator lineages acquired a median of only 0.25 muta-
tions in the 34 studied genes per year of infection, sequential
mutator lineages accumulated over three mutations per year,
representing a 13-fold higher rate. Consequently, the pro-
portion of mutator isolates was dramatically increased among
CF isolates containing a growing number of total mutations.
For example, as illustrated in Fig. 1, the proportion of muta-
tors increased from 16.7% when all isolates were considered
to 87.5% in isolates containing at least seven mutations.
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Interestingly, the increased accumulation of mutations in
mutator isolates was not the consequence of an over-repre-
sentation of mutations in genes involved in antimicrobial
resistance, which is the only adaptive trait that had been
linked so far to hypermutation in isolates from CF patients,
demonstrating that hypermutation has a generalized effect on
P. aeruginosa evolution and adaptation during CRI. For exam-
ple, of the two genes showing a higher number of mutations
in late CF isolates, one (mexZ) was involved in antibiotic
resistance and the other (lasR) was involved in quorum sens-
ing regulation and virulence; the acquisition of mutations in
both genes was equally greatly enhanced in mutators
compared to non-mutators. Further recent transcriptome
and proteome analysis of sequential isolates from CF patients
has revealed that mutators play also a role in the metabolic
adaptation of P. aeruginosa during CRI, which includes up-reg-
ulation of the anaerobic arginine deaminase pathway, anaero-
bic and microaerobic respiration, and the tricarboxylic acid
cycle and glyoxylate shunt [82]. Fig. 2 shows a schematic
representation of the evolution (adaptation) of P. aeruginosa
during CF chronic lung infection and the role of mutators as
catalyzers of the process.
These results are consistent with other recent ﬁndings in
the CF mouse model of chronic colonization, in which
P. aeruginosa mutator strains were shown to favour long-
term persistence even in the absence of antimicrobial ther-
apy [85]. Indeed, as illustrated in Fig. 3, the mutS-deﬁcient
strain clearly outcompeted wild-type PAO1 after long-term
colonization, most likely through the increased rate of
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FIG. 1. Percentages of mutators and non-mutators among cystic
ﬁbrosis isolates showing a growing number of mutations in 34 genes,
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FIG. 2. Schematic representation of the evolution (adaptation) of Pseudomonas aeruginosa during cystic ﬁbrosis chronic lung infection and the








































FIG. 3. Percentages of cystic ﬁbrosis (CF) mice showing Pseudomonas
aeruginosa-positive cultures in which PAODmutS outcompetes PAO1
(Competition Index, CI > 1) over time, as described by Mena et al. [85].
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agreement with recent studies demonstrating that the inacti-
vation of the MMR system favours the emergence of multiple
P. aeruginosa phenotypic variants in vitro, including lasR and
mucA (mucA22) mutants [86–88], the typical markers of CF
lung infection.
It should be noted, however, that the shortcut to genetic
adaptation to the airways of CF patients mediated by muta-
tors is not expected to be free of cost. Although the acquisi-
tion of mutations under a positive selective pressure should
speed up adaptation, it may also lead to the accumulation of
mutations deleterious for secondary environments. Indeed,
adapted mutator lineages recovered from mice with CF were
previously shown to reduce transmissibility [85]. Similarly,
cross-transmission of mutator lineages among CF patients
has not yet been observed, in contrast to documented
dissemination of non-mutator strains with early adaptive
mutations such as those in lasR or mucA [54]. Moreover,
mutator isolates recovered from late CRI in CF patients have
been shown to have a reduced ﬁtness and virulence once
they are retrieved from their primary lung environment
[52,59]. Finally, recent studies have evaluated the effect of hy-
permutation in the development and evolution of P. aeruginosa
bioﬁlms, which are a hallmark of chronic infections. Spontane-
ousmutation has indeed been shown to be increased during bio-
ﬁlm growth of wild-type strains as a consequence of
endogenous oxidative stress, and the generated phenotypic
diversity is considered to play a major role in the persistence of
bioﬁlm-driven infections [89–91]. A recent study by Conibear
et al. [92] has shown that MMR-deﬁcient strains, accumu-
lating further spontaneous mutations in bioﬁlms, notably
promote the growth and evolution of the characteristic
microcolonies.
Clinical Impact of Mutator Strains of
P. aeruginosa in CF
As discussed above, the tight link between mutator pheno-
types and antimicrobial resistance in itself should be consid-
ered as having major negative clinical consequences, severely
compromising the efﬁcacy of currently used antipseudomonal
agents. Perhaps less obviously, the clear link to several other
adaptive mutations assumed to play a role in the persistence
of the chronic infection might also be considered as muta-
tor-related negative clinical outcomes.
Nevertheless, the quantiﬁcation of the effect of mutators
on disease progression and deterioration of the lung function
is certainly not an easy task; it was attempted in two recent
studies carried out by Waine et al. [62] and Ferroni et al.
[63]. Waine et al. [62] investigated 40 CF patients from the
UK and found a statistically signiﬁcant poorer lung function
in CF patients in whom mutator strains where detected
(40%), showing a lower % predicted FEV1 (40 vs. 57) and a
lower mean FEV1/FVC (53 vs. 64).
Similarly, Ferroni et al. [63] investigated 36 CF patients
(with mutators detected in 50%) from France, also docu-
menting a signiﬁcant association with poorer lung function
(median % FEV1 of 43 vs. 69). Although the presence of
mutators is thus clearly linked to a poorer lung function, as
observed in both studies, several factors complicate the
assessment of mutators as independent risk factors. Among
them, the duration of the CRI appears to be particularly rel-
evant; it is well known that both the prevalence of mutators
and the deterioration of the lung function progressively
increase with the duration of the CRI, making it difﬁcult,
without further longitudinal clinical studies, to determine
whether mutators are the cause or their presence is the
consequence of lung function decline.
The presence of mixed mutator–non-mutator populations
is also a potentially relevant factor; the probability that a
given CF patient is catalogued as ‘colonized with mutators’
should thus be highly inﬂuenced by the number of sputum
samples examined, and, as noted by Waine et al. [62],
patients with poorer lung function contributed many more
samples to the study.
Future Directions
The consequences of the high prevalence of mutators have
been mostly studied with respect to P. aeruginosa, whereas
corresponding information regarding other CF pathogens is
still limited. Certainly, one of the most important aspects to
be considered in future studies is an investigation of the opti-
mal therapeutical approaches that should be used in attempts
to minimize the impact of mutators.
Avoiding the selection of mutator strains in the ﬁrst place
(i.e. before adaptation to chronicity is reached) should be
the ideal approach. Whether the early aggressive antibiotic
treatments, as currently recommended for lung infections
with P. aeruginosa in CF patients, would also be beneﬁcial for
this purpose needs to be further explored. Finally, additional
studies are required to determine the best therapeutic strat-
egies for avoiding the development of multiple antimicrobial
resistance once mutator strains have emerged in the lungs of
CF patients. The acquisition of adaptive mutations and lung
function decline are also among the consequences attributed
to P. aeruginosa mutators in chronic infections in CF patients,
although further prospective clinical studies are still needed
for a thorough evaluation of the impact of mutators on
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disease progression. These studies should include a larger
longitudinal and cross-sectional evaluation of the dynamics of
mutator populations in the CF lung. Moreover, to fully
understand the potential role of mutators in the physiopa-
thology of CF disease, we still need to gain insight into the
spatial and physical distribution of mutators within the lungs.
The determination of whether they are mainly selected in
the conductive or respiratory zones, and from planktonic
populations or alginate-producing bioﬁlm communitites, is
expected to be decisive with respect to their contribution to
the lung disease [93]. An additional evaluation of the inter-
host dynamics of mutator in comparison with non-mutator
populations should be useful for assessing the impact of
hypermutation on the epidemiology and control of chronic
infections in CF centres.
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